Zoetis Faces Class Action Lawsuit Reminder for Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Zoetis for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 14, 2025, and May 6, 2026, with a deadline to contact the firm by July 27, 2026.
- Market Misrepresentation: The complaint alleges that Zoetis made false and misleading statements during the class period, leading to investor losses when the truth emerged, particularly as its Librela medication faced declining veterinarian prescription growth due to FDA safety warnings.
- Declining Market Share: Zoetis's Trio product lost market share to competitors, while its Apoquel and Cytopoint dermatology products also suffered from newly launched competing treatments, exacerbating the company's financial challenges.
- Legal Implications: With the class action not yet certified, investors who choose not to act will remain absent class members and may miss out on potential recovery, prompting the Schall Law Firm to encourage affected investors to participate actively to safeguard their rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 79.570
Low
130.00
Averages
154.20
High
200.00
Current: 79.570
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zoetis Faces Class Action Lawsuit Reminder for Investors
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Zoetis for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 14, 2025, and May 6, 2026, with a deadline to contact the firm by July 27, 2026.
- Market Misrepresentation: The complaint alleges that Zoetis made false and misleading statements during the class period, leading to investor losses when the truth emerged, particularly as its Librela medication faced declining veterinarian prescription growth due to FDA safety warnings.
- Declining Market Share: Zoetis's Trio product lost market share to competitors, while its Apoquel and Cytopoint dermatology products also suffered from newly launched competing treatments, exacerbating the company's financial challenges.
- Legal Implications: With the class action not yet certified, investors who choose not to act will remain absent class members and may miss out on potential recovery, prompting the Schall Law Firm to encourage affected investors to participate actively to safeguard their rights.
See More
Reminder of Zoetis Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Zoetis made false or misleading statements regarding its flagship products' market share growth and sales acceleration while failing to disclose the weakening veterinarian prescription growth and market share losses, resulting in investor damages.
- Market Reaction: Following FDA safety warnings regarding Zoetis' products, investor confidence has declined, leading to significant market share losses, particularly in canine treatment products, which adversely affects the company's overall performance.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions, having secured hundreds of millions in settlements, and was ranked number one in 2017 for the number of securities class action settlements, demonstrating its expertise and successful track record in this field.
See More
Zoetis Shareholder Class Action Notice
- Lawsuit Background: The Gross Law Firm has issued a notice encouraging shareholders who purchased Zoetis (NYSE: ZTS) shares between January 14, 2025, and May 6, 2026, to contact them regarding potential lead plaintiff status, indicating significant legal risks for the company.
- Declining Market Share: The lawsuit alleges that Zoetis' products, Librela and Simparica Trio, have seen a sharp decline in growth as veterinarians become cautious following FDA safety warnings, which could adversely affect the company's future revenues.
- Increased Competition: Zoetis' dermatology products, Apoquel and Cytopoint, are losing substantial market share to newly launched competing treatments, highlighting the company's vulnerable position in the highly competitive pet healthcare market.
- Shareholder Action Recommendation: Shareholders are advised to register for the class action by July 27, 2026, and will receive real-time updates on the case's progress, ensuring their rights are protected.
See More
Class Action Filed Against Zoetis for Investor Losses
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Zoetis in the Southern District of New York on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026, alleging the company failed to disclose critical adverse information, resulting in investor losses.
- Declining Market Share: The lawsuit claims that Zoetis' products, Librela and Simparica Trio, experienced significant market share declines as veterinarian prescription growth weakened, particularly following FDA safety warnings, undermining investor confidence in the company's prospects.
- Increased Competition: Zoetis' dermatology products, Apoquel and Cytopoint, are reportedly losing substantial market share to newly launched competing treatments, highlighting the company's vulnerability in a highly competitive market environment.
- Investor Rights Protection: Investors must apply by July 27, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering no-cost legal consultations to assist affected investors in protecting their rights.
See More
Zoetis Faces Class Action Lawsuit Reminder for Investors
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Zoetis for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 14, 2025, and May 6, 2026, with a deadline to contact the firm by July 27, 2026.
- Market Misrepresentation Issues: The complaint alleges that Zoetis made false and misleading statements during the class period, primarily due to weakening veterinarian prescription growth for its Librela medication following FDA safety warnings, resulting in investor losses.
- Declining Market Share: Zoetis's Trio product has lost market share to competitors, while its Apoquel and Cytopoint dermatology products have also been adversely affected by the introduction of new competing treatments, exacerbating the company's market challenges.
- Investor Losses: As the market became aware of the true situation regarding Zoetis, investors suffered significant losses, prompting the Schall Law Firm to encourage affected investors to join the lawsuit for compensation, highlighting serious concerns over corporate governance and transparency.
See More
Multiple Companies Facing Class Action Lawsuits
- Calix, Inc. Lawsuit: During the period from January 28 to April 21, 2026, Calix is accused of concealing that its first-quarter margins benefited from advanced purchasing of memory components, leading to a misunderstanding of the company's prospects, which could negatively impact its stock performance.
- AeroVironment, Inc. Allegations: From June 25, 2025, to March 10, 2026, AeroVironment is accused of underestimating imminent competition for the SCAR program, resulting in overstated business prospects that could undermine investor confidence.
- Zoetis Inc. Issues: Between January 14 and May 6, 2025, Zoetis allegedly failed to disclose that veterinarian prescription growth was sharply weakening due to FDA safety warnings, which could lead to a decline in market share and affect future earnings.
- Lucid Group, Inc. Lawsuit: From February 25 to April 13, 2026, Lucid faced significant delivery disruptions due to supplier quality issues, which materially impacted its business and financial results, potentially causing losses for investors.
See More
Zoetis Faces Class Action Lawsuit Reminder for Investors
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Zoetis for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 14, 2025, and May 6, 2026, with a deadline to contact the firm by July 27, 2026.
- Market Misrepresentation: The complaint alleges that Zoetis made false and misleading statements during the class period, leading to investor losses when the truth emerged, particularly as its Librela medication faced declining veterinarian prescription growth due to FDA safety warnings.
- Declining Market Share: Zoetis's Trio product lost market share to competitors, while its Apoquel and Cytopoint dermatology products also suffered from newly launched competing treatments, exacerbating the company's financial challenges.
- Legal Implications: With the class action not yet certified, investors who choose not to act will remain absent class members and may miss out on potential recovery, prompting the Schall Law Firm to encourage affected investors to participate actively to safeguard their rights.
See More
Reminder of Zoetis Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Zoetis made false or misleading statements regarding its flagship products' market share growth and sales acceleration while failing to disclose the weakening veterinarian prescription growth and market share losses, resulting in investor damages.
- Market Reaction: Following FDA safety warnings regarding Zoetis' products, investor confidence has declined, leading to significant market share losses, particularly in canine treatment products, which adversely affects the company's overall performance.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions, having secured hundreds of millions in settlements, and was ranked number one in 2017 for the number of securities class action settlements, demonstrating its expertise and successful track record in this field.
See More
Zoetis Shareholder Class Action Notice
- Lawsuit Background: The Gross Law Firm has issued a notice encouraging shareholders who purchased Zoetis (NYSE: ZTS) shares between January 14, 2025, and May 6, 2026, to contact them regarding potential lead plaintiff status, indicating significant legal risks for the company.
- Declining Market Share: The lawsuit alleges that Zoetis' products, Librela and Simparica Trio, have seen a sharp decline in growth as veterinarians become cautious following FDA safety warnings, which could adversely affect the company's future revenues.
- Increased Competition: Zoetis' dermatology products, Apoquel and Cytopoint, are losing substantial market share to newly launched competing treatments, highlighting the company's vulnerable position in the highly competitive pet healthcare market.
- Shareholder Action Recommendation: Shareholders are advised to register for the class action by July 27, 2026, and will receive real-time updates on the case's progress, ensuring their rights are protected.
See More
Class Action Filed Against Zoetis for Investor Losses
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Zoetis in the Southern District of New York on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026, alleging the company failed to disclose critical adverse information, resulting in investor losses.
- Declining Market Share: The lawsuit claims that Zoetis' products, Librela and Simparica Trio, experienced significant market share declines as veterinarian prescription growth weakened, particularly following FDA safety warnings, undermining investor confidence in the company's prospects.
- Increased Competition: Zoetis' dermatology products, Apoquel and Cytopoint, are reportedly losing substantial market share to newly launched competing treatments, highlighting the company's vulnerability in a highly competitive market environment.
- Investor Rights Protection: Investors must apply by July 27, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering no-cost legal consultations to assist affected investors in protecting their rights.
See More
Zoetis Faces Class Action Lawsuit Reminder for Investors
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Zoetis for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 14, 2025, and May 6, 2026, with a deadline to contact the firm by July 27, 2026.
- Market Misrepresentation Issues: The complaint alleges that Zoetis made false and misleading statements during the class period, primarily due to weakening veterinarian prescription growth for its Librela medication following FDA safety warnings, resulting in investor losses.
- Declining Market Share: Zoetis's Trio product has lost market share to competitors, while its Apoquel and Cytopoint dermatology products have also been adversely affected by the introduction of new competing treatments, exacerbating the company's market challenges.
- Investor Losses: As the market became aware of the true situation regarding Zoetis, investors suffered significant losses, prompting the Schall Law Firm to encourage affected investors to join the lawsuit for compensation, highlighting serious concerns over corporate governance and transparency.
See More
Multiple Companies Facing Class Action Lawsuits
- Calix, Inc. Lawsuit: During the period from January 28 to April 21, 2026, Calix is accused of concealing that its first-quarter margins benefited from advanced purchasing of memory components, leading to a misunderstanding of the company's prospects, which could negatively impact its stock performance.
- AeroVironment, Inc. Allegations: From June 25, 2025, to March 10, 2026, AeroVironment is accused of underestimating imminent competition for the SCAR program, resulting in overstated business prospects that could undermine investor confidence.
- Zoetis Inc. Issues: Between January 14 and May 6, 2025, Zoetis allegedly failed to disclose that veterinarian prescription growth was sharply weakening due to FDA safety warnings, which could lead to a decline in market share and affect future earnings.
- Lucid Group, Inc. Lawsuit: From February 25 to April 13, 2026, Lucid faced significant delivery disruptions due to supplier quality issues, which materially impacted its business and financial results, potentially causing losses for investors.
See More
